Doctors track Kids' growth and health on psoriasis drug
Disease control
Ongoing
This study is monitoring the long-term safety of the psoriasis medication ustekinumab in children and teenagers aged 6 to 17. Researchers are watching for potential side effects related to the immune system, such as serious infections or autoimmune reactions. They are also tracki…
Sponsor: Janssen-Cilag International NV • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC